Bis((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)diphosphonic acid

Catalog No. :
ACHPZX831
CAS No. :
1607007-18-0
Molecular Formula :
C18H26N10O7P2
Molecular Weight :
556.42

IUPAC Name:Bis((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)diphosphonic acid

Bis((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)diphosphonic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
10mg98%$621.00Login to see priceInquiryInquiry
25mg98%$884.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameBis((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)diphosphonic acid
IUPAC NameBis((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)diphosphonic acid
Molecular FormulaC18H26N10O7P2
Molecular Weight556.42
SMILESNC1=C(N=C2)C(N2C[C@@H](C)OCP(OP(CO[C@H](C)CN3C4=NC=NC(N)=C4N=C3)(O)=O)(O)=O)=NC=N1
InChI KeyBJZVJNQCJKIBSO-VXGBXAGGSA-N
SynonymTenofovir Alafenamide PMPA Impurity;bis((((S)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)diphosphonic acid;TAF Impurity D;Tenofovir Alafenamide Impurity 12;Tenofovir alafenamide-18;Tenofovir related Impurity 3(Tenofovir Alafenamide Impurity 8);Tenofovir impurity P0Z19 (PMPA anhydride);Tenofovir related Impurity 3
CAS No.1607007-18-0

Safety Data

Pictogram
Toxic
Signal Word
Gefahr
Hazard Statement(s)
H301
Precautionary Statement(s)
P264-P270-P301+P310+P330-P405-P501

Synthetic Route by SureRoute

1. ACHPZX831 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACHPZX831 route product structure diagram
    ACHPZX8311607007-18-0
Inquiry

2. ACHPZX831 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACHPZX831 route product structure diagram
    ACHPZX8311607007-18-0
Inquiry

Comments (0)